ENHERTU (fam-trastuzumab deruxtecan-nxki)

for the treatment of unresectable or metastatic HER2-positive breast cancer

• DOSAGE FORMS： For injection
• STRENGTHS： 100 mg lyophilized powder in a single-dose vial
• Manufactured by： Daiichi Sankyo, Inc.
• ACTIVE INGREDIENT： fam-trastuzumab deruxtecan-nxki